Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection.

ABSTRACT:

Background & aims

Hepatocellular carcinoma (HCC) prediction models can inform clinical decisions about HCC screening provided their predictions are robust. We conducted an external validation of 6 HCC prediction models for UK patients with cirrhosis and a HCV virological cure.

Methods

Patients with cirrhosis and cured HCV were identified from the Scotland HCV clinical database (N = 2,139) and the STratified medicine to Optimise Treatment of Hepatitis C Virus (STOP-HCV) study (N = 606). We calculated patient values for 4 competing non-genetic HCC prediction models, plus 2 genetic models (for the STOP-HCV cohort only). Follow-up began at the date of sustained virological response (SVR) achievement. HCC diagnoses were identified through linkage to nation-wide cancer, hospitalis

SUBMITTER: Innes H 

PROVIDER: S-EPMC8585647 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature